T he pivotal role of vitamin D in calcium homeostasis and bone metabolism is well known. More recently, vitamin D insufficiency has been linked to many nonskeletal health problems and chronic diseases. 1,2 Vitamin D has pleiotropic effects that may favorably influence cardiovascular health through multiple mechanisms, including downregulation of the renin-angiotensin system, 3 enhancement in insulin secretion and insulin sensitivity, 4,5 protection against angiogenesis, 6 and modulation of inflammatory processes. 7 Cross-sectional and retrospective case-control studies have shown deficient (typically defined as <25 nmol/L; to convert to ng/mL, divide by 2.496) or insufficient (25-50 nmol/L) levels of circulating 25-hydroxy-vitamin D (25[OH]-vitamin D, the standard biomarker for vitamin D status) in patients with established cardiovascular disease (CVD). 8-10 Prospective studies found mixed results; some, 11-14 but not all, 15,16 reported an inverse association between baseline circulating 25(OH)vitamin D and subsequent risk of CVD. Overall, existing evidence supports the hypothesis that low 25(OH)-vitamin D is associated with increased risk of CVD. 17,18 However,
a closer investigation of prior studies indicates that the association between 25(OH)-vitamin D and CVD risk may be nonlinear and reach a plateau between 50 and 75 nmol/L. 19 Others have suggested a possible U-shaped relation, with a slight increase in CVD risk at both low (<50 nmol/L) and high (>125 nmol/L) levels of 25(OH)-vitamin D. 11, 16 The shape of the vitamin D and CVD association over the wide spectrum of 25(OH)-vitamin D levels has yet to be determined.
The current dietary recommendations for vitamin D by the Institute of Medicine 20 are based on vitamin D required for bone health. The Institute of Medicine determined that the evidence was insufficient to address the amount of vitamin D that may be beneficial for CVD. With widespread attention to a possible role of vitamin D in the prevention of CVD, it becomes increasingly important to further evaluate the doseresponse association between vitamin D status and CVD and to determine the optimal 25(OH)-vitamin D level that may confer potential cardiovascular benefits. We therefore conducted a systematic review and a meta-analysis to quantitatively assess the association between circulating 25(OH)-vitamin D concentrations and CVD risk in prospective studies, focusing on the dose-response gradient.
Methods

Data Sources and Literature Search Strategy
We identified the pertinent published literature through a systematic search of MEDLINE and EMBASE from 1966 through February 2012. We selected generic and specific search terms related to vitamin D and CVD on the basis of an analysis of the Medical Subject Headings and text words from a priori identified key articles. Search terms used for vitamin D included vitamin D, 25(OH)-vitamin D, 1,25-dihydroxy-vitamin D, calcidiol, and calcitriol. Search terms used for CVD included CVD, ischemic heart disease, coronary artery disease (coronary heart disease), cardiovascular mortality, myocardial infarction, and stroke. The search results using vitamin D-related terms and CVD-related terms were then combined. We further restricted the search to English-language articles, human studies, and adult subjects ≥18 years of age. The same set of search terms and search strategies was applied to each database. We also manually searched the reference lists of selected articles for additional studies. More details on the literature search strategy are presented in the online-only Data Supplement.
Study Selection
The studies eligible for inclusion were prospective studies that examined the association between circulating concentrations of 25(OH)vitamin D at baseline and risk of CVD events during follow-up. Studies were excluded if they were (1) ecological, cross-sectional, or retrospective case-control studies because of concerns about the directionality of association and the potential bias from reverse causation; (2) review articles, commentaries, editorials, or case reports; (3) studies that did not measure circulating 25(OH)-vitamin D; (4) studies that did not ascertain major clinical CVD events including CVD death, myocardial infarction, or stroke as end points; (5) studies that did not compare CVD event rates between different 25(OH)-vitamin D concentrations; and (6) studies of participants selected by confirmed medical conditions (such as diabetes mellitus or end-stage kidney disease). Articles that passed the abstract screening were retrieved for a full-text review. Two investigators (Wang and Song) independently reviewed all identified articles and assessed each study for adherence to the selection criteria. The interrater reliability, calculated as the percentage of agreement between 2 investigators, is 98%.
Data Extraction
Two investigators (Wang and Song) extracted key data from the selected articles using a standardized form and independently verified the extracted data for completeness and accuracy. Disagreements were reconciled through group discussion. For each article, we extracted data on the authors, year of publication, location of the study, study design, participant characteristics, duration of follow-up, number of cases and noncases for each CVD end point, category of circulating 25(OH)vitamin D level, covariates adjusted for in multivariable analyses, and estimates of association (relative risk [RR] or odds ratio and 95% confidence interval [CI] ). For studies conducted in different subsamples of the same cohort, we extracted data of each publication separately. When necessary, missing information (including number of cases and noncases in each category of 25[OH]-vitamin D and estimates of association) was obtained by direct contact with the original study authors.
Data Synthesis and Analysis
We first reported original data of the selected articles in a summary table. To maximize statistical power for hypothesis testing, we performed meta-analyses to combine estimates of association across all studies using DerSimonian and Laird's random-effects model in which each study is weighted by the inverse of the sum of withinstudy plus between-study variance. 21 Because odds ratios in nested case-control studies were close estimates for RRs, we refer to all association estimates as RRs. The pooled RR of total CVD with 95% CI was calculated by comparing the lowest with the highest category of 25(OH)-vitamin D level, as well as per standard unit decrease in continuous 25(OH)-vitamin D when data were available. We also examined the associations of 25(OH)-vitamin D with death resulting from CVD, coronary heart disease, and stroke separately.
Heterogeneity across studies was assessed by the Cochran Q, I 2 , and H statistics. The percentages of I 2 around 25% (I 2 =25), 50% (I 2 =50), and 75% (I 2 =75) indicate low, medium, and high heterogeneity, respectively. An H statistic <1.2 indicates little heterogeneity and an H>1.5 raises caution about notable heterogeneity. We assessed publication bias using visual inspection of the Begg modified funnel plots, in which the RR was plotted on a logarithmic scale (log[RR]) against its standard error from each study, the Begg adjusted rank correlation test, and the Egger regression asymmetry test.
We assessed the dose-response association between 25(OH)vitamin D and risk of CVD using a fractional polynomial spline regression analysis. We also used the method described by Greenland and Longnecker 22 to test the linear trend from the
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• Vitamin D has pleiotropic effects that may favorably influence cardiovascular health. • Cross-sectional and retrospective case-control studies found deficient or insufficient levels of circulating 25-hydroxy-vitamin D in patients with established cardiovascular disease.
WHAT THE STUDY ADDS
• Baseline circulating 25-hydroxy-vitamin D was inversely associated with the risk of cardiovascular disease in majority, but not all, of prospective studies. • The inverse association was consistent in various subgroup analysis stratified by study characteristics. • The increment of cardiovascular disease risk with decreasing 25-hydroxy-vitamin D was generally linear over the range of 25-hydroxy-vitamin D from 20 to 60 nmol/L (8-24 ng/mL).
correlated RRs and 95% CIs across multiple categories of continuous variable. The median level of 25(OH)-vitamin D in each category reported in the original study was assigned to the corresponding RR. If not reported, the values assigned were the mean or the midpoint of the lower and upper bounds in each category.
For the extreme open-ended categories, half of the width of adjacent category was subtracted (for the lowest category) or added (for the uppermost category) to obtain the midpoint. These methods to assign exposure level for analysis of dose-response relation have been reported previously. 23 Analyses were further stratified to examine the difference in pooled RRs by baseline age of participants, duration of follow-up, number of CVD cases, 25(OH)-vitamin D assay methods, exclusion of baseline CVD, and control for key confounders, including age, sex, season of blood collection, body mass index, and physical activity. Sensitivity analyses were conducted to evaluate the robustness of the pooled estimates. All analyses were performed with the STATA software (version 10.1, STATA Corp, College Station, TX). Statistical significance was defined as 2-tailed α<0.05.
Results
A total of 1469 articles were identified through the literature search, of which 24 articles met our inclusion criteria ( Figure 1 ). The characteristics of these studies, including 22 cohort 11,13-16,24-40 and 2 nested case-control studies, 12, 41 are shown in the online-only Data Supplement Table. All studies provided the RRs of CVD according to categories of 25(OH)-vitamin D concentration, and 10 studies provided the RRs in association with continuous 25(OH)-vitamin D. 11, 12, 25, 27, 32, 33, 35, 37, 38, 41 One study examined coronary heart disease and stroke separately 15 and 1 study examined smokers and nonsmokers separately. 34 These results were considered independent studies in pooled analysis. When multiple studies were conducted in the same cohort, the study with larger sample size and/or more complete data 16, 25, 32, 38 was included for pooled analysis. As a result, the final meta-analysis included 19 individual studies that reported data on categorical 25(OH)vitamin D, with 10 studies also reporting data on continuous 25(OH)-vitamin D. Table 1 shows the results of each study included in the meta-analysis.
We used multivariable RRs that adjusted for conventional CVD risk factors, including hypertension, diabetes mellitus, and hypercholesterolemia, reported in each study for the pooled analysis. The primary analysis included a total of 6123 CVD cases from 65 994 participants. Figure 2 shows the study-specific and the pooled RRs for total CVD comparing the lowest with the highest categories of 25(OH)vitamin D level (pooled RR=1.52, 95% CI, 1.30-1.77). The P value for heterogeneity from the Cochran Q test (Q=45.9, df=18) was 0.0003, suggesting that the variations between studies were not solely attributable to sampling variation. The I 2 (61; 95% CI, Limited to human studies, English-language, adults ≥18 y N=623 541 excluded based on abstract review Review, editorial, letter, short survey, or note: N=81 Case report: N=72 Did not assess circulating vitamin D as exposure: N=287 Did not ascertain CVD events: N=296 Limited to human studies, English-language, adults ≥18 y N=846 736 excluded based on abstract review Review, editorial, letter to editor: N=131 Case report: N=94 Did not assess circulating vitamin D as exposure: N=228 Did not ascertain CVD events: N=389 A total of 19 independent studies included for meta-analysis Search terms for cardiovascular disease included cardiovascular disease (CVD), ischemic heart disease, coronary artery disease, cardiovascular mortality, myocardial infarction, and stroke. Initial search results were further limited to English-language articles, human studies, and studies of adults ≥18 years of age. In each box, the sum of studies in all categories may exceed the total number because of overlapping classification.
Table 1. Estimates of Association Between Circulating 25(OH)-Vitamin D Concentrations and Risk of CVD in 19 Prospective Studies Included in the Meta-analysis
CVD End Point
Estimates of Association On the basis of available data for specific CVD events, the random-effects pooled RRs were 1.42 (95% CI, 1.19-1.71) for CVD mortality, 1.38 (95% CI, 1.21-1.57) for coronary heart disease, and 1.64 (95% CI, 1.27-2.10) for stroke, comparing the lowest with the highest categories of 25(OH)vitamin D. In stratified analyses to assess potential sources of heterogeneity between studies, the inverse association between 25(OH)-vitamin D and risk of CVD was consistent regardless of the age of participants, number of CVD cases, 25(OH)-vitamin D assay methods, exclusion of baseline CVD, and control for key confounders in the individual studies ( Table 2 ). Associations seemed stronger in the studies that followed up participants for <10 years and attenuated when the follow-up time was longer (P for interaction = 0.005). Figure 3 shows the dose-response association between circulating 25(OH)-vitamin D and risk of CVD based on 16 studies that provided complete data on RRs of CVD according to each category of 25(OH)-vitamin D. Overall, the test for a linear relation across the range of 25(OH)-vitamin D from 20 up to 140 nmol/L was marginally significant (P=0.06). The CVD risk increased monotonically across decreasing 25(OH)vitamin D concentration below ≈60 nmol/L, with a pooled RR of 1.03 (95% CI, 1.00-1.06) per 25-nmol/L decrement in 25(OH)-vitamin D. There was no clear increase or decrease in CVD risk with 25(OH)-vitamin D >60 nmol/L based on the few data points. When the analysis was restricted to those studies that excluded participants with baseline CVD and were better controlled for confounding, 12, 27, 33, 38, 41 the pooled RR for CVD per 25-nmol/L decrement in 25(OH)-vitamin D was 1.07 (95% CI, 1.03-1.12).
In sensitivity analyses, we first evaluated the influence of individual studies on the pooled RRs of CVD comparing the lowest versus highest category of 25(OH)-vitamin D. We omitted 2 small studies that reported very strong associations, 14,41 1 study 25 that was not population-based, and 1 study 34 that used an assay found to overestimate 25(OH)-vitamin D. 42 Subsequently, we repeated tests for linear trend of the dose-response association between 25(OH)-vitamin D and risk of CVD by assigning different exposure values to the open-ended categories of 25(OH)-vitamin D. The results did not change materially in these sensitivity analyses (data not shown).
Discussion
Our meta-analysis of prospective observational studies showed an inverse association between baseline circulating 25(OH)vitamin D concentrations and risk of CVD with considerable heterogeneity between studies. Comparing the lowest with the highest category of 25(OH)-vitamin D concentration, the pooled RR for total CVD was 1.52 (95% CI, 1.30-1.77). The increment of CVD risk with decreasing 25(OH)-vitamin D was generally linear over the range of 25(OH)-vitamin D from 20 to 60 nmol/L, with a modest and marginally significant pooled RR of 1.03 (95% CI, 1.00-1.06) per 25 nmol/L decrement in 25(OH)-vitamin D. These associations remained significant when the analyses were restricted to the studies that excluded participants with baseline CVD and were better controlled for confounding. A large body of evidence from laboratory studies suggests that vitamin D potentially has beneficial effects on cardiovascular risk factor profiles and the development of CVD. [3] [4] [5] [6] [7] Population studies have shown favorable associations of circulating vitamin D with CVD risk factors, particularly hypertension, 43 impaired glucose tolerance or type 2 diabetes mellitus, 44 and inflammation. 45 In clinical studies, circulating 25(OH)-vitamin D was low in patients with myocardial †One study provided results that excluded and did not exclude participants with baseline cardiovascular disease separately. ‡Control for a minimum of confounders including age, sex, season of blood collection, BMI, and physical activity.
infarction, 8 stroke, 9 and peripheral arterial disease. 10 Despite the promising data from cross-sectional and retrospective case-control studies, results of prospective studies on the association between baseline 25(OH)-vitamin D and subsequent incidence of CVD events remain inconsistent. Our systematic review of the literature, in line with earlier reviews, 17, 18 found that the majority, albeit not all, prospective studies support an association between low circulating 25(OH)-vitamin D and increased risk of CVD events. The pooled RRs demonstrated a strong, highly significant, inverse association. Although there is considerable heterogeneity between individual studies, stratified analysis found that the inverse association was consistent in various study subgroups. A stronger association was found in studies with <10 years of follow-up than those with longer follow-up, which may reflect changes in 25(OH)vitamin D over longer periods of time or the competing risks for fatal and nonfatal diseases in older populations. Some previous studies have suggested a possible nonlinear association, with a threshold effect or even a U-shaped relation, between 25(OH)-vitamin D and risk of CVD. 11, 16 Because of the limited data and the heterogeneity between studies, especially with respect to the categories of 25(OH)vitamin D used, CVD outcomes prespecified, and confounders adjusted for, the optimal levels of 25(OH)-vitamin D for cardiovascular health have yet to be determined. To resolve this uncertainty, we specifically examined the dose-response association and found it to be generally linear for 25(OH)vitamin D ranging from 20 to ≈60 nmol/L. The trend of linear association over the broad spectrum of 25(OH)-vitamin D up to 140 nmol/L was marginally significant, with a pooled RR for CVD of 1.03 per 25-nmol/L decrement in 25(OH)-vitamin D when all studies were included and 1.07 when limited to the studies that excluded participants with baseline CVD and were better controlled for confounding. The linear association seemed stronger when combining data from 10 studies that reported the RR of CVD in association with continuous 25(OH)-vitamin D, presumably because of differences in data source, levels of 25(OH)-vitamin D, and modeling strategy. We further evaluated the individual studies with extreme circulating 25(OH)-vitamin D levels. We found that the lowest category of 25(OH)-vitamin D previously studied was <25 nmol/L; in 3 studies 11,25,41 that reported the results, all showed significant associations between low 25(OH)-vitamin D and increased risk of CVD. In contrast, in 8 studies that examined 25(OH)-vitamin D >65 nmol/L in the comparison group versus a higher reference (with 1 study examining multiple categories well above 85 nmol/L), 6 found no significant change in the risk of CVD, suggesting a possible threshold effect.
Because our meta-analysis is based on observational study data, the result is subject to potential bias in all observational studies. Although potential confounders such as age, body mass index, and physical activity have been adjusted for in individual studies, residual confounding cannot be ruled out. Causality underlying the observed association and the effect of vitamin D supplement on cardiovascular health cannot be addressed in our analysis and remain to be determined in future studies. Preliminary findings from clinical trials have suggested that vitamin D supplementation may reduce cardiovascular mortality 46 or CVD event rate, 47 supporting a possible role of vitamin D in CVD prevention. Nevertheless, existing trial data are insufficient and inconclusive. There is suggestive evidence that a moderate to high vitamin D exposure may be needed for the prevention of CVD. 48 It should be noted that the Women's Health Initiative Calcium-Vitamin D trial, in which 36 282 postmenopausal women were assigned to take calcium (1000 mg/d) plus vitamin D 3 (400 IU/d) or placebo for 7 years, found no reduction in coronary heart disease or stroke incidence with combined calcium and vitamin D supplementation. 49 One of the most plausible reasons is that the vitamin D dose used in the Women's Health Initiative was too low to change circulating vitamin D levels significantly. 49 Although randomized trials are important to establish the causality of the vitamin D-CVD relation, their inferences are commonly linked with a single dose of vitamin D that yields a narrow change rather than a full spectrum of 25(OH)-vitamin D. Our meta-analysis of prospective observational studies allows an evaluation of the dose-response association between vitamin D and CVD risk over a broad range of 25(OH)-vitamin D levels, which will not only complement findings from ongoing randomized trials but also help to inform future trials that test the effect of vitamin D supplements on CVD in terms of the optimal doses. This meta-analysis has several potential limitations. First, because our analyses were based on published studies, publication bias is a concern. We therefore performed visual inspection of plot and formal tests and found no evidence of substantial publication bias. Second, some individual studies that reported very strong associations may have influenced the meta-analysis results. We conducted sensitivity analyses, in which a similar pooled RR was yielded after removal of the studies with extreme RRs. Third, the optimal 25(OH)-vitamin D for cardiovascular health may differ by race/ethnicity. Because virtually all existing studies were conducted among predominantly white cohorts, we were unable to assess race/ ethnicity-specific associations between vitamin D and CVD, even after combining data in this meta-analysis. Finally, the potential bias in each individual study and high heterogeneity between studies preclude any definitive conclusions.
Despite the controversy on causation, improving vitamin D status has been proposed as a promising strategy for CVD prevention. Given the high prevalence of vitamin D insufficiency in the general US population, the potential public health impact of vitamin D improvement would be substantial. Current dietary guidelines for vitamin D by the Institute of Medicine 20 that recommend 600 IU/d for persons 1 to 70 years of age and 800 IU/d for persons >70 years of age, corresponding to a circulating 25(OH)-vitamin D of 50 nmol/L or more assuming minimal sun exposure, are solely based on the beneficial effect of vitamin D on bone health. The Institute of Medicine report concluded that evidence was insufficient to demonstrate that vitamin D protects against CVD and called for additional research to elucidate this association. Our meta-analysis based on existing literature showed that low levels of circulating 25(OH)-vitamin D are associated with an increased risk of CVD. The dose-response curve between 25(OH)-vitamin D and CVD risk indicated that the association was generally linear across the range of 25(OH)-vitamin D from 20 to 60 nmol/L with a marginally significant trend. More prospective studies and randomized, clinical trials are needed to further clarify the association between 25(OH)-vitamin D >60 nmol/L and CVD risk and to assess the causality of observed associations.
